Lung cancer, breast cancer, gastric cancer, colorectal cancer, liver cancer, esophageal cancer, pancreatic cancer, prostate tumors, kidney cancer, ovarian cancer, cervical cancer, and other solid tumors.
Technical Advantages：
Multidisciplinary evaluation covering a broad range of systemic therapies, including ADCs, targeted therapy, immunotherapy, endocrine therapy, and chemotherapy. These therapies can be combined with local treatments, providing a broader range of treatment combinations for complex cases and patients who have received multiple lines of therapy.
Call Now —
Get Expert Advice
Limited Treatment Options? Reassess Your Options in China
Based on pathology, genetic testing, and previous treatment history, we assess potential options including ADCs, targeted therapy, immunotherapy, endocrine therapy, chemotherapy, and combination treatment.
Global Originator Drugs + Chinese InnovationMultidisciplinary Team (MDT) AssessmentRemote Preliminary Assessment in Approximately 1–3 Business Days
01
You May Be Facing These Concerns
1You already know the name of a treatment or target, but are unsure whether it is right for you
Whether ADCs, targeted therapy, immunotherapy, or endocrine therapy are suitable cannot be determined by a drug name or another patient’s experience alone. A comprehensive assessment is needed based on the cancer type, pathological and molecular features, stage of treatment, and previous treatment history.
2Treatment options are limited locally, and you want to know whether China offers other possibilities
China has extensive cancer care resources and continues to introduce and develop new treatment technologies. When the current treatment is no longer effective or cannot be continued, the case can be reassessed from multiple perspectives, including systemic therapy, precision radiation therapy, minimally invasive interventional treatment, and surgery. Even after treatment resistance, local progression, or metastases to multiple sites, there may still be new treatment approaches worth exploring.
3You have already received multiple lines of therapy or developed treatment resistance and are unsure what options are still available
Progression after multiple lines of therapy does not necessarily mean that there are no further options. Doctors need to reassess previous medications, the timing of resistance, sites of progression, the latest imaging findings, and molecular testing results. Some patients may also require pathology review or repeat genetic testing. Based on this reassessment, new systemic therapies, local radiation therapy, or other combination treatment options may still be considered.
4Treatment is expensive locally, and you want an estimate of treatment costs in China
You can first submit your medical records and previous treatment plans. Based on the potential treatment approach, expected duration, and whether combination therapy may be needed, we can provide a preliminary cost range to help you plan your budget before traveling to China.
From Cancer Type and Molecular Targets to Treatment Strategy — Reassessing Your Options
Patients with the same type of cancer may follow very different treatment pathways depending on pathological subtype, genetic alterations, previous treatment, and patterns of resistance. The overview below is intended to help patients quickly understand the treatment approaches that may be considered for different cancers. It is not a complete treatment guide.
ADC Therapy
Antibody-drug conjugates (ADCs) use antibodies to recognize specific tumor targets and deliver their drug payload more selectively to the area around or inside tumor cells. They have become an important systemic treatment option for certain cancers.
Targeted Therapy
Targeted therapy is selected according to genetic alterations or biomarker results and is commonly used in lung cancer, breast cancer, gastrointestinal cancers, and many other malignancies.
Immunotherapy
Immunotherapy helps the body’s immune system recognize and attack cancer cells. Whether it is suitable depends on factors such as cancer type, stage, PD-L1 and other relevant biomarkers, and previous treatment history.
Endocrine Therapy
Endocrine therapy is mainly used for certain hormone-dependent cancers, such as some breast and prostate cancers. During treatment, subsequent options can be reassessed based on the pattern of resistance and molecular testing results.
Chemotherapy and Combination Treatment
Conventional chemotherapy remains an important treatment for many cancers and is also frequently combined with targeted therapy, immunotherapy, radiation therapy, and other approaches.
Note: Our hospital provides standardized in-hospital diagnosis and treatment. We do not sell medications separately, purchase medications on patients’ behalf, or ship medications. All treatments are provided in the hospital only after physicians have assessed the indication and treatment safety.
What Treatment Options May Be Considered for Different Cancers?
Common Cancer Types
Potential Systemic Treatment Options
Non-Small Cell Lung Cancer
Therapies targeting EGFR / ALK / ROS1 / MET / RET / KRAS and other molecular alterations, immunotherapy, chemotherapy and combination treatment, ADC therapy
Breast Cancer
HER2-directed targeted therapy / ADCs, endocrine therapy + targeted agents such as CDK4/6 inhibitors, TROP2-directed ADCs, immunotherapy
Gastric / Gastroesophageal Junction Cancer
HER2-directed targeted therapy / ADCs, immunotherapy, chemotherapy and combination treatment, CLDN18.2-directed therapy for CLDN18.2-positive disease
Colorectal Cancer
Anti-EGFR targeted therapy, anti-angiogenic therapy, immunotherapy for MSI-H / dMMR tumors, chemotherapy and combination treatment
Hepatocellular Carcinoma
Targeted and anti-angiogenic therapy, immunotherapy and combination treatment
Esophageal Cancer
Immunotherapy, chemotherapy and combination treatment
Kidney Cancer
Targeted and anti-angiogenic therapy, immunotherapy and combination treatment
Prostate Cancer
Endocrine therapy, androgen receptor pathway-targeted therapy, chemotherapy, and other systemic treatments
Note: The options above represent only some commonly considered treatment approaches and are not suitable for every patient. Specific indications, treatment sequence, combination strategies, and availability at our hospital must be assessed by a physician based on pathological subtype, cancer stage, genetic and biomarker findings, previous treatment history, and overall health.
Why Do International Patients Consider Cancer Treatment in China?
1MDT Assessment to Identify a More Suitable Treatment Combination
Our hospital uses a multidisciplinary team (MDT) approach involving medical oncology, surgery, radiation oncology, and other relevant specialties. The goal is not simply to add more treatments, but to coordinate systemic and local therapies according to the individual patient’s condition, allowing different treatment modalities to complement one another and improve the chances of disease control.
2International Standards + Chinese Innovation for Broader Treatment Options
Cancer care in China includes established treatment approaches aligned with international practice, while domestic innovation, clinical research, and new treatment technologies continue to advance. Newer treatments may differ between countries and regions in when they become available, their indications, clinical accessibility, and cost. Seeking treatment in China may therefore provide additional possibilities in treatment selection, continuity of care, and cost planning, creating more options for subsequent treatment.
3Timely Treatment Initiation with Less Waiting
When complete medical records are available, a remote preliminary assessment generally takes 1–3 business days. Once a hospital visit is confirmed, consultations and examinations can be arranged in advance. After arrival, necessary examinations can usually begin on the same day or the following day, and treatment can be started as soon as the required results are available, helping reduce unnecessary waiting and repeated travel.
4Transparent Costs for More Predictable Cross-Border Care
As a tertiary non-profit general hospital, our hospital charges according to applicable medical service pricing policies. Before traveling to China, international patients can receive an approximate cost range for examinations, hospitalization, and treatment at each stage. The expected budget is further confirmed before formal treatment begins, and any cost changes are communicated if the treatment plan is adjusted. Itemized statements are provided after treatment, making it easier for patients and families to plan the overall course of care.
According to the patient’s previous medical records, he had received four cycles of chemotherapy. An EGFR exon 19 deletion was subsequently identified, and he received multiple lines of targeted therapy as well as local radiation therapy. The disease later continued to progress, with widespread bone metastases and new liver metastases, accompanied by sacroiliac pain. The patient did not wish to undergo chemotherapy again and came to our hospital to explore other treatment options.
Our Reassessment and Treatment Approach
After admission, the team developed a combined treatment strategy of “systemic therapy + local precision radiation therapy” based on the patient’s condition and treatment preferences.
Local Treatment: VMAT precision radiation therapy was delivered to painful and progressive lesions in the pelvis, lumbar spine, and other affected areas to relieve symptoms and improve local tumor control.Systemic Treatment: After reassessing previous treatment resistance and the patient’s overall condition, the systemic treatment regimen was adjusted, with response and tolerability monitored throughout subsequent treatment cycles.
Interim Results
After completing local radiation therapy and receiving four rounds of systemic therapy, the patient underwent follow-up CT on August 18, 2026:
Metastatic lymph nodes in the right hilar region and small bilateral pulmonary nodules had decreased slightly in size; multiple liver and abdominal metastatic lesions had decreased significantly. The overall interim response was assessed as partial response (PR). The patient’s pain had also improved, and treatment was continued according to the existing regimen.
Note: This is an individual case showing an interim treatment outcome and does not imply that other patients will achieve the same result. Treatment plans must be individualized by physicians according to each patient’s condition.
From Medical Record Submission to Specialist Recommendations in Just Four Steps
1
Medical Record Submission
Pathology reports, imaging studies, genetic / biomarker test results, previous treatment records, and a list of current medications.
2
Preliminary Specialist Assessment
Based on the cancer type, pathological subtype, tumor stage, genetic testing results, and overall health, the specialist identifies treatment options that may warrant further evaluation.
3
Treatment Options and Preliminary Cost Estimate
Based on the available records, we outline possible systemic, local, or combination treatment approaches and provide preliminary information on examinations after arrival in China, expected treatment duration, and estimated cost ranges.
4
Consultation and Visit Coordination
An online consultation or outpatient appointment can be arranged, with assistance for hospital visits, admission, medical interpretation, and subsequent treatment coordination.
🌐 Professional Medical Interpretation🚗 Private Airport / High-Speed Rail Station Transfer💰 Transparent Pricing with Itemized Statements💬 Visa / Admission Assistance
07
Frequently Asked Questions from International Patients
1How can I tell whether ADCs, targeted therapy, immunotherapy, or endocrine therapy are suitable for me?
Suitability cannot be determined from the name of a drug or treatment category alone. Doctors need to evaluate the cancer type, pathological and molecular features, stage of treatment, previous therapies, and overall health. You can first submit your pathology, imaging, and genetic testing reports for a preliminary remote assessment.
2Can Chinese hospitals use pathology and genetic testing reports from overseas?
Yes. These reports can initially be used for a remote preliminary assessment. If the information is incomplete, the results are unclear, or further confirmation is required before treatment, doctors may recommend pathology review, repeat imaging, or additional testing after admission. Whenever possible, please provide clear copies of the original reports together with the original imaging files.
3Can I still receive systemic therapy if I am physically weak?
Whether treatment is appropriate depends on a comprehensive assessment of performance status, complete blood count, liver and kidney function, cardiopulmonary function, infection risk, and underlying medical conditions. Recent laboratory results and medical records can first be submitted for preliminary remote screening. Whether the patient can tolerate treatment can only be determined after a full in-hospital assessment.
4What side effects may occur, and can they be managed at the hospital?
The type and severity of adverse effects vary by treatment and can differ considerably between patients. Before treatment, the patient’s baseline health is assessed, and the treatment goals, potential benefits, common risks, and alternative treatment options are explained. Treatment is provided only after the patient has been fully informed. During treatment, blood counts, liver and kidney function, and other relevant parameters are monitored according to the specific regimen. Any adverse effects that occur are managed promptly with appropriate symptomatic and supportive care.
5Why do doctors pay so much attention to HER2, EGFR, and PD-L1 results?
These biomarkers can help doctors identify tumor characteristics that may be relevant to treatment. For example, certain EGFR alterations may indicate potential targeted therapy options; HER2 status can affect the choice of HER2-directed targeted therapy or ADCs; and in some cancers, PD-L1 is an important factor when assessing whether immunotherapy may be appropriate. However, no single biomarker can determine the treatment plan on its own. Cancer type, stage, previous treatment, and overall health must all be considered together.
+ 86 17688273501
Address
Email Form
Language
English
Hotline Phone+ 86 17688273501
Back to Menu
